[Influenza vaccination of hospital healthcare staff from the perspective of the employer: a positive balance].
OBJECTIVE
To assess the annual productivity loss among hospital healthcare workers attributable to influenza and to estimate the costs and economic benefits of a vaccination programme from the perspective of the the employer.


METHODS
Cost-benefit analysis.


METHODS
The percentage of work loss due to influenza was determined using monthly age and gender specific figures for productivity loss among healthcare workers of the University Medical Center Groningen (UMCG), the Netherlands over the period January 2006-June 2008. Influenza periods were determined on the basis of national surveillance data. The average increase in productivity loss in these periods was estimated by comparison with the periods outside influenza seasons. The direct costs of productivity loss from the perspective of the employer were estimated using the friction cost method. In the sensitivity analyses various modelling parameters were varied, such as the vaccination coverage.


RESULTS
In the UMCG, with approximately 9,400 employees, the estimated annual costs associated with productivity loss due to influenza before the introduction of the yearly influenza vaccination program were € 675,242 or on average, € 72 per employee. The economic benefits of the current vaccination program with a vaccination coverage of 24% with a vaccine effectiveness of 71% were estimated at € 89,858 or € 10 per employee. The nett economic benefits of a vaccination program with a target vaccination coverage of 70% with a vaccine effectiveness of 71% were estimated at € 244,325 or € 26 per employee.


CONCLUSIONS
This modelling study performed from the perspective of the employer showed that an annual influenza vaccination programme for hospital personnel can save costs.
Rijksuniversiteit Groningen, Groningen Research Institute for Pharmacy (GRIP), unit Farmaco-epidemiologie & Farmaco-economie (FE2), Groningen, the Netherlands.
Eelko
E
Hak
Lisanne M
LM
Knol
Jan C
JC
Wilschut
Maarten J
MJ
Postma
D003362:Cost-Benefit Analysis; D006801:Humans; D007252:Influenza Vaccines / Q000008:administration & dosage* / Q000191:economics*; D007251:Influenza, Human / Q000191:economics / Q000453:epidemiology / Q000517:prevention & control*; D009426:Netherlands; D010564:Personnel, Hospital / Q000191:economics; D012621:Seasons; D018582:Sick Leave / Q000191:economics*
D007252:Influenza Vaccines